Effect of Wine Consumption on Cardiovascular Markers in CHDs Patients

Effect of Light to Moderate Wine Consumption on Cardiovascular Markers in Coronary Heart Disease Patients

Many epidemiological studies support that 20-30gr of alcohol consumption per day is related with lower risk for cardiovascular diseases, heart attack as well as mortality related to these diseases. Since the French paradox was reported, a number of experimental and clinical studies have demonstrated the protective effect of red wine compared to other alcoholic drinks on different pathways of the pathogenesis of atherosclerosis. The investigator's previous results revealed that wine contain micro-constituents that exert potent in vitro anti-platelet and anti-inflammatory actions. Also, the wine consumption along with a standardized meal reduced platelet aggregation and biosynthesis of Platelet Activating Factor in healthy men.

Although a large number of studies have reported protective effect of wine against atherosclerosis in healthy people there are few data about the effect of long-term moderate wine consumption in population with CVD. Therefore, the aim of this randomized, intervention clinical study, with control group was to report the effects of regular light to moderate wine consumption on cardiovascular biomarkers in people with CVD.

Study Overview

• Status: Completed
• Conditions: Cardiovascular Disease
• Intervention / Treatment: Other: Cabernet Sauvignon; Other: Tsipouro

Detailed Description

The study was a randomized, controlled, three-arm parallel intervention study, designed to evaluate if the light to moderate wine consumption could modulate thrombosis and inflammation, in patients with cardiovascular disease. The study was carried out in accordance with the guidelines laid down in the Declaration of Helsinki (1989) of the World Medical Association and was approved by the Bioethics Committee of Harokopio University. Seventy one men patients with cardiovascular disease were initially recruited to participate in the study. The recruitment took place in several hospitals of Athens in Greece under the supervisor of corresponding cardiologist. Finally 64 met the inclusion criteria. Prior to intervention all participants signed an informed consent All volunteers followed an initial 15 days wash-out period, abstaining from alcohol; then, they randomly assigned to one of the three intervention groups. The randomization code was prepared by a staff member who was not involved in running the trial, by using computer-generated random numbers. Subjects instructed to follow their usual diet and not change their medication during the study. In Group A (control group), participants consumed no alcohol, in Group B (ethanol group) participants consumed 69 mL of tsipouro with 38% alcohol and participants in Group C consumed 200ml of red wine (Cabernet Sauvignon 13.5% alcohol vol.). The ethanol that was consumed in the last two groups was equal at 27gr of ethanol per day and alcoholic beverage was consumed along with the meal (lunch or dinner). Finally, 57 participants completed the study, in particular 20 in Group A, 16 in Group B and 21 in Group C. Intervention lasted two months and biological samples (blood, urine) were collected at the beginning (0 week), in the middle (4 week) and in the end (8 week) of each intervention.

• Study Type: Interventional
• Enrollment (Actual): 57
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Greece
  • Athens, Greece, 17671
    • Department of Nutrition-Dietetics, Harokopio University

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 37 years to 82 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Male

Description

Inclusion Criteria:

The presence of Coronary Heart disease established by angiography or the presence of one of the following:

1. positive stress test
2. positive myocardial perfusion scintigraphy with Thallium
3. positive triplex heart ultrasound with Dobutamine

If nothing of the criteria above existed then hospitalization because of myocardial infarction or stroke.

Stable medication for at least 6 months.

Habit to drink 10-28gr of alcohol per week.

Exclusion Criteria:

History of any other inflammatory disease, diabetes, presence of cold or flu, acute respiratory infection, dental problems and renal/hepatic diseases.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Red Wine group; Participants of this group consumed 200ml of red wine along with a meal (lunch or dinner) every day for 8 weeks.	Other: Cabernet Sauvignon; Cabernet Sauvignon is a red wine from a greek company which contains 13.5% alcohol vol.
Active Comparator: Ethanol group; Participants of this group consumed 69mL of tsipouro along with a meal (lunch or dinner) every day for 8 weeks.	Other: Tsipouro; Tsipouro is a greek spirit which contains 38% alcohol vol
No Intervention: Control group; Participants of this group consumed no alcohol along with a meal (lunch or dinner) every day for 8 weeks

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Effect on platelet aggregation against PAF	% Change of EC50 value of platelet aggregation against PAF	Changes between baseline, 4 and 8 weeks.
Effect on platelet aggregation against ADP	% Change of EC50 value of platelet aggregation against ADP	Changes between baseline, 4 and 8 weeks.
Effect on platelet aggregation against collagen	% Change of EC50 value of platelet aggregation against collagen	Changes between baseline, 4 and 8 weeks.
Effect on inflammatory markers (activity of Lyso-PAF-AT)	% Change in the activity of PAF biosynthetic enzyme Lyso-PAF AT	Changes between baseline, 4 and 8 weeks.
Effect on inflammatory markers (activity of PAF-CPT)	% Change in the activity of PAF biosynthetic enzyme PAF-CPT	Changes between baseline, 4 and 8 weeks.
Effect on inflammatory markers (activity of PAF-AH)	% Change in the activity of PAF degradation enzyme PAF-AH	Changes between baseline, 4 and 8 weeks.
Effect on inflammatory markers (activity of LpPLA2)	% Change in the activity of PAF degradation enzyme Lp-PLA2	Changes between baseline, 4 and 8 weeks.
Effect on inflammatory markers	% Changes of Adiponectin, IL-6, CRP	Changes between baseline, 4 and 8 weeks.
Cytokine secretion by PBMC	Secretion of TNFa and IL-1β by PBMC under basal and inflammatory (LPS-induced) conditions at 4 and 24h incubation	Changes between baseline, 4 and 8 weeks.
Effect on endothelial function markers	% Changes of VCAM, P-selectin.	Changes between baseline, 4 and 8 weeks.

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Effect on biochemical indices	% Changes of Total cholesterol, LDL-chol, HDL-chol, triacylglycerols, uric acid, glucose, insulin, SGOT/AST, SGPT/ALT, γ-GT	Changes between baseline, 4 and 8 weeks.
Effect on oxidative stress markers	% Changes of TBARS, Lag time, GPx	Changes between baseline, 4 and 8 weeks.

Collaborators and Investigators

• Sponsor: Harokopio University

Study record dates

Study Major Dates

• Study Start (Actual): September 1, 2013
• Primary Completion (Actual): June 1, 2018
• Study Completion (Actual): June 1, 2018

Study Registration Dates

• First Submitted: June 16, 2020
• First Submitted That Met QC Criteria: June 18, 2020
• First Posted (Actual): June 18, 2020

Study Record Updates

• Last Update Posted (Actual): June 18, 2020
• Last Update Submitted That Met QC Criteria: June 18, 2020
• Last Verified: June 1, 2020

More Information

Terms related to this study

• Keywords: platelet aggregation; cardiovascular disease; inflammatory biomarkers; ethanol; PBMCs; wine; Platelet Activating Factor; Wine microcontsituents
• Additional Relevant MeSH Terms: Cardiovascular Diseases
• Other Study ID Numbers: HarokopioU

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No